Executives On The Move: Bayer Elects New Chairman, J&J Vision Exec Makes A Change for Eyevance And CureVac Decides On Candidate For Rare Diseases Post
Executive Summary
Bayer AG elects a new chairman, to begin serving at the end of April. US ophthalmic products firm Eyevance Pharma brings on board a former J&J Vision exec as chief commercial officer, and German mRNA company CureVac AG appoints a new head of rare diseases.